These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15109663)

  • 1. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.
    Borhani DW; Calderwood DJ; Friedman MM; Hirst GC; Li B; Leung AK; McRae B; Ratnofsky S; Ritter K; Waegell W
    Bioorg Med Chem Lett; 2004 May; 14(10):2613-6. PubMed ID: 15109663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
    Burchat A; Borhani DW; Calderwood DJ; Hirst GC; Li B; Stachlewitz RF
    Bioorg Med Chem Lett; 2006 Jan; 16(1):118-22. PubMed ID: 16216497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection.
    Stachlewitz RF; Hart MA; Bettencourt B; Kebede T; Schwartz A; Ratnofsky SE; Calderwood DJ; Waegell WO; Hirst GC
    J Pharmacol Exp Ther; 2005 Oct; 315(1):36-41. PubMed ID: 16014572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
    Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
    J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
    Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
    J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 7-N-piperazinylthiazolo[5,4-d]pyrimidine analogues as a novel class of immunosuppressive agents with in vivo biological activity.
    Jang MY; Lin Y; De Jonghe S; Gao LJ; Vanderhoydonck B; Froeyen M; Rozenski J; Herman J; Louat T; Van Belle K; Waer M; Herdewijn P
    J Med Chem; 2011 Jan; 54(2):655-68. PubMed ID: 21171614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disubstituted pyrimidines as Lck inhibitors.
    Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cheng A; Faust T; Hsieh F; Huang X; Lee JH; Marshall TL; Martin MW; McGowan DC; Schneider S; Turci SM; White RD; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2305-9. PubMed ID: 17280833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection.
    Waegell W; Babineau M; Hart M; Dixon K; McRae B; Wallace C; Leach M; Ratnofsky S; Belanger A; Hirst G; Rossini A; Appel M; Mordes J; Greiner D; Banerjee S
    Transplant Proc; 2002 Aug; 34(5):1411-7. PubMed ID: 12176420
    [No Abstract]   [Full Text] [Related]  

  • 18. Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection.
    Kamens JS; Ratnofsky SE; Hirst GC
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1213-9. PubMed ID: 11717807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
    Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
    J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.